TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

LUV00996 The provision of services for formulation development, clinical batch manufacture and distribution of the active pharmaceutical ingredient (API), Resveratrol: the COLO-PREVENT study

Research and development services and related consultancy services
UK
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: University of Leicester: "LUV00996 The provision of services for formulation development, clinical batch manufacture and distribution of the active pharmaceutical ingredient (API), Resveratrol: the COLO-PREVENT study". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityUniversity of LeicesterScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: University of Leicester
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for University of Leicester. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
3.8Bids / Report
20% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 10 active published awards; 10 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityUniversity of Leicester
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published14 Oct 2021, 12:15 BST
Last source update14 Oct 2021, 12:15 BST
Recurring procurementNot published
ClassificationResearch and development services and related consultancy services
Delivery area
UK
OCIDocds-h6vhtk-02a187
What is being bought
LUV00996 The provision of services for formulation development, clinical batch manufacture and distribution of the active pharmaceutical ingredient (API), Resveratrol: the COLO-PREVENT study
What changed
From the official release history
  1. tender value changed
    14 Oct 2021, 12:15 BST
  2. Status changed to complete
    14 Oct 2021, 12:15 BST
  3. Official notice release published
    14 Oct 2021, 12:15 BST
  4. Submission deadline changed to published date
    14 Oct 2021, 12:15 BST
  5. Published value updated to £1,057,433
    31 Mar 2021, 14:32 BST
  6. Status changed to active
    31 Mar 2021, 14:32 BST
  7. Official notice release published
    31 Mar 2021, 14:32 BST
  8. Submission deadline changed to 6 May 2021, 12:00 BST
    31 Mar 2021, 14:32 BST
  9. Buyer information updated
    31 Mar 2021, 14:32 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    cancelled
    Published valueNot published
    LUV00996 The provision of services for formulation development, clinical batch manufacture and distribution of the active pharmaceutical ingredient (API), Resveratrol: the COLO-PREVENT study. COLO-PREVENT will assess whether intervention with the API resveratrol is able to affect recurrence of colorectal adenomas within the NHS Bowel Cancer Screening Programme. Award of contract is dependent on: a)prior receipt by the University of an award letter from the funder (CRUK) and b) a cap on the overall budget of £1,268,920 including VAT at 20%.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    14 Oct 2021, 12:15 BST
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 13 Oct 2021, 00:00 BST · £1,036,511
Commercial outcome and competition
Awards
Catalent Nottingham Limited
Not published · Not published · active
Contracts
Contract
£1,036,511 · signed 13 Oct 2021, 00:00 BST · active
Bid statistics
bids: 2 (lot 1)
electronicBids: 2 (lot 1)
foreignBidsFromEU: 0 (lot 1)
foreignBidsFromNonEU: 2 (lot 1)
smeBids: 1 (lot 1)
Buyer and organisations in this procedure

University of Leicester

Contracting authority GB-FTS-3723
View buyer profile

  • University of Leicester
    buyer

    University Road, Leicester, UK, LE1 7RH
    acm26@le.ac.uk
    +44 1162522058

  • Catalent Nottingham Limited
    supplier

    03397582
    8 Orchard Place, Nottingham Business Park, Nottingham, UK, NG8 6PX

  • Royal Courts of Justice
    reviewBody

    Strand, London, WC2A 2LL

  • See VI.4.1 above
    mediationBody

    See VI.4.1 above

  • See VI.4.1 above
    reviewContactPoint

    See above
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published